HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 126 participants.

Also called NCT07123779

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 126 participants (planned count) (from the registry)
Sponsor
35Pharma Inc., a GSK company (from the registry)
Registry
  • NCT NCT07123779
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07123779. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-21 (actual); primary completion 2029-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Intervention (Biological)
HS235
Intervention (Other)
Placebo
Lead sponsor
35Pharma Inc., a GSK company (class: industry)

Record details

Record id
cardio:ct-nct07123779
Content hash
b751b97e7acf8af347009d699d19c661c39a25915ee0e6d87005c945fe3a6e39